Success Metrics

Clinical Success Rate
84.1%

Based on 53 completed trials

Completion Rate
84%(53/63)
Active Trials
10(13%)
Results Posted
32%(17 trials)
Terminated
10(13%)

Phase Distribution

Ph phase_4
9
11%
Ph not_applicable
4
5%
Ph phase_3
5
6%
Ph phase_1
41
51%
Ph phase_2
19
24%

Phase Distribution

41

Early Stage

19

Mid Stage

14

Late Stage

Phase Distribution78 total trials
Phase 1Safety & dosage
41(52.6%)
Phase 2Efficacy & side effects
19(24.4%)
Phase 3Large-scale testing
5(6.4%)
Phase 4Post-market surveillance
9(11.5%)
N/ANon-phased studies
4(5.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.5%

53 of 65 finished

Non-Completion Rate

18.5%

12 ended early

Currently Active

10

trials recruiting

Total Trials

80

all time

Status Distribution
Active(12)
Completed(53)
Terminated(12)
Other(3)

Detailed Status

Completed53
Terminated10
Recruiting7
Active, not recruiting3
unknown3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
80
Active
10
Success Rate
84.1%
Most Advanced
Phase 4

Trials by Phase

Phase 141 (52.6%)
Phase 219 (24.4%)
Phase 35 (6.4%)
Phase 49 (11.5%)
N/A4 (5.1%)

Trials by Status

enrolling_by_invitation11%
active_not_recruiting34%
completed5366%
not_yet_recruiting11%
recruiting79%
unknown34%
terminated1013%
withdrawn23%

Recent Activity

Clinical Trials (80)

Showing 20 of 80 trialsScroll for more
NCT06507904Phase 1

A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults

Not Yet Recruiting
NCT06481306Phase 1

A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease

Recruiting
NCT04488081Phase 2

I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Active Not Recruiting
NCT06154226Phase 2

Prevention of Post-Cardiac Surgery Acute Kidney Injury by Proton Pump Inhibitor

Completed
NCT07101445Phase 4

Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial

Recruiting
NCT04918147Phase 2

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

Terminated
NCT06207305Phase 1

A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma

Recruiting
NCT05455359Phase 4

Gastrointestinal Dysmotility on Aspiration Risk

Recruiting
NCT05077332Phase 2

LEAP-CT for Treatment of COVID-19 Patients (Master Protocol)

Completed
NCT05035407Phase 1

T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

Terminated
NCT07018635Phase 1

A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants

Completed
NCT05977998Phase 2

A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

Recruiting
NCT06213818Phase 1

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of INCB160058 When Administered Orally to Healthy Adult Participant

Completed
NCT06743243Phase 4

Effect of Tegoprazan for Elective Surgery Patients Under General Anesthesia

Enrolling By Invitation
NCT04862585Phase 2

Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel

Completed
NCT03805932Phase 1

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Active Not Recruiting
NCT04614974Phase 1

Initiation of Acid Suppression Therapy Prospective Outcomes for Laryngomalacia

Terminated
NCT05946551Phase 3

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

Terminated
NCT05965492Phase 3

Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery

Withdrawn
NCT06819670Phase 2

A Study to Prevent Infantile Spasms Relapse

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
80